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48 As the most abundant bioactive polyphenol in green tea, epigallocatechin gallate 
49 (EGCG) is a promising natural product that should be utilized in the discovery and 
50 development of potential drug leads. Due to its association with chemoprevention, 
51 EGCG may find a role in the development of therapeutics for prostate cancer. 
52 Natural products have long been employed as a scaffold for drug design, as their 
53 already noted bioactivity can help accelerate the development of novel treatments. 
54 Green tea and the EGCG contained within have become associated with 
55 chemoprevention, and both in vitro and in vivo studies have correlated EGCG to 
56 inhibiting cell growth and increasing the metabolic stress of cancer cells, possibly 
57 giving merit to its long utilized therapeutic use in traditional therapies. There is 
58 accumulating evidence to suggest that EGCG’s role as an inhibitor of the 
59 PI3K/Akt/mTOR signaling cascade, acting upon major axis points within cancer 
60 survival pathways. The purpose of this review is to examine the research conducted 
61 on tea along with EGCG in the areas of the treatment of and/or prevention of cancer. 
62 This review discusses Camellia sinensis, as well as the bioactive phytochemical 
63 compounds contained within. Clinical uses of tea are explored, and possible 
64 pathways for activity are discussed before examining the evidence for EGCG’s 
65 potential for acting on these processes. EGCG is identified as being a possible lead 
66 phytochemical for future drug design investigations.    
67




71 There are multiple strategies when it comes to drug design, including de novo 
72 design, structure-based, target-based screening, pharmacophore searching; 
73 however, one of the longest standing approaches is the study of natural products. 
74 Isolation of bioactive components within natural products can lead to a stand-alone 
75 treatment or present a structural basis for a more efficient novel drug design. Green 
76 tea is one such natural product and has been traditionally administered for 
77 therapeutic use. Large cohort studies have hinted at a positive correlation between 
78 green tea consumption and cancer chemoprevention in men diagnosed with prostate 
79 cancer  [1-6].  It has been discovered that one of green tea’s most prominent 
80 bioactive component, the flavanol (-)-epigallocatechin gallate (EGCG), is likely the 
81 source of this activity [3, 7-12]. EGCG has been noted to influence key enzymes in 
82 the PI3K/Akt/mTOR pathway, which is commonly dysregulated in the development of 
83 prostate cancer, and could potentially act in a similar form to the synthetic inhibitors 
84 being developed against this pathway [13]. Despite its potential, work still needs to 
85 be done to identify whether green tea or EGCG can be recommended as a 
86 chemopreventative.[13]. Much of the large cohort evidence struggles to differentiate 
87 between the effect of consuming green tea and lifestyle choices [14]. Thus although 
88 there are multiple claims and evidence to suggest the benefit of EGCG for cancer 
89 therapy, more research is needed in both the therapeutic mechanisms of actions and 
90 the clinical benefit. By reviewing literature in these areas, the relevance of this 






96 This study utilized a series of medical databases, inclusive of PubMed, EMBASE, 
97 MedLine, and SciFinder for articles published in the past 20 years to obtain a viable 
98 and comprehensive depiction of our current understanding of EGCG and its potential 
99 involvement in minimizing the deregulated of biochemical pathways observed in 
100 cancers. Search strategies began with using keywords such as “epigallocatechin 
101 gallate” AND “prostate cancer”, or more generally “green tea” AND “metastasis”. As 
102 data were collected and the interacting pathways better comprehended, the search 
103 requests expanded to more expansively investigate the involved PI3K/Akt/mTOR 
104 pathway, history, and previous association of green tea as a chemopreventive 
105 medicine, and studies investigating the modern approach to targeting the metabolic 
106 pathways of cancer. 
107
108
109 3. Green Tea. Source and Bioactivity. 
110
111 3.1 Botanical Source
112
113 EGCG is most abundantly found in green tea; however, it is also present in black 
114 and oolong teas, along with trace amounts found in miscellaneous fruit and 
115 vegetables [15]. All three of the major tea varieties including black, oolong, and 
116 green, are sourced from the Camellia sinensis plant, which grows globally in warm 
117 and humid climates [16]. China, Indonesia, Sri Lanka, and southern India have a 
118 year-round harvesting and growing season, whereas areas such as northern-eastern 
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119 India and northern China have a shorter season due to the greater seasonal 
120 variations [17]. The Camellia Sinensis is harvested by hand, with the “flush,” 
121 consisting of the top leaves connected to the bud and part of the stem making up the 
122 basis of tea [18]. It is during the processing of this flush where the black, green, and 
123 oolong tea varieties differ (Figure 1). For green tea, the flushes are withered and 
124 rolled, then either steamed or pan-roasted to inactivate the polyphenol oxidases 
125 within the plant [19]. From here, green tea is relatively stable during storage until 
126 seeping. This varies from the processing of black and oolong tea, as they lack the 
127 primary steaming step performed in green tea, and consequentially have a lower 
128 proportion of bioactive components in the final product [20-22]. 
129
130 3.2 Active Components in Green Tea
131
132 Amongst the wide variety of bioactive components in green tea, the polyphenols are 
133 the most abundant (Figure 2). Compromising around 40% of green tea’s dry mass, 
134 these compounds are colorless and water-soluble, contributing to the bitterness of 
135 the final product [20, 23]. Other compounds including the stimulatory 
136 methylxanthines, caffeine, theobromine, and theophylline are also present in tea, 
137 along with L-theanine, tannins, gallic acid, oxalic acid, pectin, fluoride, minerals and 
138 vitamins such as B1, B2, C, and E which can be found at varying concentrations, the 
139 most predominant category are the flavonoids [24, 25]. Characterized by their 2-
140 phenylbenzopyran ring, variations in the C-ring saturation and oxidation status of 
141 flavonoids divide the classifications up into eight different groups, in which the flavan-
142 3-ols are the most abundant (Figure 3).
143
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144 Compared to the darker black and oolong teas which have most of their flavanols 
145 converted into their theaflavins and thearubigins counterparts during oxidation, green 
146 tea maintains a far higher proportion of the more bioactive flavanols (Table 1) [10, 
147 26]. Such flavonoids include quercetin, kaempferol, and myricetin and the flavones 
148 apigenin and luteolin, with the largest class being the catechins [27]. By mass, 
149 epigallocatechin gallate (EGCG) is the most predominant (7–74 mg/g), followed by 
150 epicatechin gallate (ECG) (1–41 mg/g), epigallocatechin (EGC) (0–36.5 mg/g), 
151 epicatechin (EC) (0.1–9.5 mg/g) and catechin (C) (0–5.8 mg/g) [28-30] (Figure 4). 
152 However, depending on the variety, brand and location of harvest, these 
153 concentrations may vary [31]. 
154
155 3.3 Bioactive Role
156
157 Catechins are hydroxy and gallate substitutions of the flavan-3-ol structure, each 
158 with relative bioactive effects [32]. Chemotherapeutically, the gallocylated catechins, 
159 GC, EGC, GCG, and EGCG are noted to possess the most chemotherapeutically 
160 active role [33-37]. The combined use of green tea catechins has been associated 
161 with antioxidant activity, chemoprevention, anti-viral, anti-inflammatory and anti-
162 diabetic activity [38-41]. However, with the trihydroxyl groups at carbons 3’, 4’, and 5’ 
163 on the B-ring, and a gallate moiety esterified at carbon 3’ on the C-ring, EGCG 
164 presents with the greatest anti-proliferative and pro-apoptotic activity against cancer 
165 cells compared to the other catechins [3, 7-12]. 
166
167 Studies show extracting EGCG from tea is most effective at 80oC using a 50% v/v 
168 ethanol solution as this prevented epimerization of the catechin, however, if using 
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169 fresh leaves, then the extraction should use 75% v/v ethanol to compensate for the 
170 higher moisture content [42]. A later 2014 study investigating various extraction 
171 solvents, including ethanol, methanol, and water at different time intervals, 
172 concluded that a 40-minute extraction with ethanol maintained the greatest 
173 proportion of the catechins [43]. 
174
175 3.4 Clinical Uses
176
177 Records of the production and attributed health benefits of tea have dated back to 
178 the Cha Jing (Tea Bible) by the Lu Yu of the Tang Dynasty, often with a focus 
179 towards its anti-inflammatory action [44]. Such traditional Chinese medicines are still 
180 appreciated due to their theoretical approach and long-documented history [45]. 
181 Nowadays, many commercially available drugs derive inspiration from natural 
182 products, such as the chemotherapeutics topotecan and docetaxel which are 
183 synthetic alterations of the natural products camptothecin (Camptothec acuminate) 
184 and paclitaxel (Taxus brevifolia), along with Vincristine (Catharanthus roseus) which 
185 is a natural product (often synthetically generated) from the Madagascar periwinkle 
186 (Figure 5) [46]. EGCG’s association with chemoprevention has prompted investment 
187 towards furthering its potential clinical application with two studies initiated in March 
188 2018 to investigate its effect at minimizing the chemotherapeutic damage done in 






194  4. Prostate Cancer & Current Treatments
195
196 From 2015, 3300 deaths per year were attributed to prostate cancer, making it one 
197 of the leading causes of cancer-related mortality, accounting for 16% of Australia’s 
198 male cancer expenditure [49, 50]. With the major risk factor being age, patients are 
199 left with few options to decrease their susceptibility towards the disease. 
200 Consequently, greater reliance is placed upon detection and treatment [51]. If 
201 surgery or radiotherapy fails to remove the cancer growth, androgen deprivation 
202 therapy (ADT), primarily bicalutamide (trade name Casodex), serves as the first-line 
203 chemotherapeutic [49]. However, this treatment is only palliative, acting to suppress 
204 the androgen driven growth in the early stages. Within 14-30 months, ADTs typically 
205 become redundant as the cells mutate into an androgen-independent state known as 
206 castration-resistant prostate cancer (CRPCa) [49].  Whether or not CRPCa is initially 
207 metastatic, 60% of men develop the metastatic disease within five years, with most 
208 developing it within three [52].
209
210 From here, docetaxel (tradename ‘Taxotere’) is the preferred chemotherapeutic, and 
211 it is associated with extremely high rates of chemoresistance and only extends the 
212 nine months' lifespan by an average three months [49, 53-55]. Since 2010, 
213 alternative treatments including immunology, cabazitaxel, enzalutamide, and 
214 abiraterone acetate have been trailed, extending the life expectancy by up to 5 
215 months [23, 56]. However, these have been associated with a poorer quality of life 
216 than docetaxel. Some of the more common drug-based treatment options in 
217 Australia are tabulated below (Table 3).
218
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219 4.1 Green tea and Prostate Cancer 
220
221 The need for intervention, which can reduce the incidence of metastasis of Prostate 
222 Cancer (PCa) without severely hindering the quality of life, is going to be crucial to 
223 address this global health issue. In both Japanese and Chinese populations, there is 
224 a lower incidence of many cancers, including PCa, primarily attributed to their diet of 
225 soy, low fat, and high fiber as means of chemoprevention. Furthermore, their high 
226 intake of green tea has a strong positive correlation to chemoprevention [1-6]. Daily 
227 consumption of 10 or more cups a day is seen to increase the age of onset and 
228 decrease metastasis of a variety of cancers, including PCa [57-59]. Although not 
229 PCa, studies using squamous cell carcinomas cells show that the therapeutic index 
230 of 10 M can be reached with regular consumption of green tea [60]. Using a 
231 preparation known as polyphenol E, it was found that the maximum tolerable dose of 
232 green tea was 4.2 g/m2 (equivalent to 20-30 cups of green tea) when tested on 
233 metachronous colorectal cells [61, 62]. 
234
235 The primary side effects, including polydipsia and urinary frequency, were suspected 
236 to be due to the caffeine content [57, 63-65]. However, with or without caffeine 
237 present, there was no significant difference in green tea’s ability to inhibit 
238 angiogenesis in vivo [66]. Studies observing green tea’s influence over PCa cell 
239 survival show a decrease in proliferation of androgen insensitive cells due to the 





244 4.2 Bioavailability 
245
246 The primary concern regarding the use of EGCG and other green tea preparations 
247 clinically was their low bioavailability [67]. The non-gallated green tea catechins 
248 undergo glucuronidation and sulfation in vivo, preventing their chemopreventive 
249 activity [68]. This observed in patients following a 6-week trial of oral green tea 
250 consumption, where 50% of EGCG in the prostate tissue appeared in its methylated 
251 form, consequentially decreasing the chemopreventive activity in the cells [69]. 
252 However, this may be combatted by the combined use of EGCG and quercetin 
253 (another polyphenol found in tea) [70]. Quercetin was seen to inhibit the catechol-O-
254 methyltransferase and the multidrug-resistant proteins responsible for the 
255 methylation of EGCG and to improve EGCG’s chemopreventive activity [70]. 
256
257 5.0 PI3K/AKT/MTOR PATHWAY IN CANCER
258
259 To better understand EGCG’s potential clinical benefit, it is fitting to examine the 
260 likely intracellular signaling pathways affected by EGCG. It is unclear whether 
261 EGCG’s activity is pro or antioxidant [36, 71, 72], much of EGCG’s chemotherapeutic 
262 action is attributed to its influence over the PI3K/Akt/mTOR pathway. Defined by the 
263 key proteins; phosphatidylinositol 3-kinase (PI3K), protein kinase B (Akt), and 
264 mammalian target of rapamycin (mTOR), this pathway is a key regulator of 
265 metabolism, cell cycle, and preventing apoptosis; thus its hyperactivation is greatly 
266 involved in promoting the hallmarks of cancer [37, 73]. Many various carcinomas and 
267 prostate cancers observe the dysregulation of the PI3K/Akt/mTOR pathway, and this 
268 mutation is often a characteristic of chemoresistant cancer types [74].
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269
270 This pathway is typically activated in response to the binding of hormonal or 
271 mitogenic ligands to a receptor tyrosine kinase, phosphorylating the intracellular 
272 subunit and activating the p85 and p110 kinase receptor units of the PI3K 
273 heterodimer [75]. Activation induces the addition of ATP to PIP2 in the cell 
274 membrane, forming the PIP3 signaling molecule, which in turn activates the PH 
275 subunit of Akt, recruiting the protein to the cell membrane (Figure 6). This is followed 
276 by the phosphorylation of phosphoinositide-dependent protein kinase-1 at the T308 
277 residue, activating the complex [76]. Akt goes onto activate a number of intracellular 
278 signaling processes, each holding influencing cell survival, proliferation, and growth, 
279 primarily mediated through the two mTOR multiprotein complexes mTORC1 and 
280 mTORC2 [77, 78].
281
282 5.1 Pro survival and acceleration of growth
283
284 Pro-survival and growth signaling are vital to cancer progression. With control over 
285 the cell cycle and suppression of apoptosis, overactivation of the PI3K/Akt/mTOR 
286 pathway can promote cancer cell survival [79]. The activated Akt phosphorylates and 
287 inactivates glycogen synthase kinase-3 beta, preventing the activation of tumor 
288 suppressor p53 and degradation of cyclin D [80]. Akt also induces the degradation of 
289 p53 by inhibiting the transduction of nuclear-localized E3 ubiquitin ligase [81]. Now 
290 remaining active in the nucleus, CD1 binds and activates the cyclin-dependent 
291 kinase (CDK) proteins [82]. CDK4 and CDK6 inhibit the tumor suppressor 
292 retinoblastoma protein (Rb), preventing the inhibitor of transcription factors G2F and 
293 enabling the progression from G1 to S-phase [82]. This amplified through mTORC1’s 
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294 activation of ribosomal protein S6 kinase beta-1, F-box only protein 4, and inhibition 
295 of N-eukaryotic initiator factor, thus enhancing the stability of genes involved in S-
296 phase entry [83]. Akt further ensures the activity of CDKs by inhibiting p21Cip1/Waf and 
297 p27Kip1 [84, 85]. Direct phosphorylation of p21 also inhibits proliferating cell nuclear 
298 antigen, a suppressor of DNA replication [86]. Thus, in a multifactorial mechanism, 
299 the activation of the Akt pathway promotes and protects the progression through the 
300 cell cycle. Studies have observed that the cell cycle can be arrested at the G1 phase 
301 through the inhibition of PI3K [87]. 
302
303 Another vital aspect of cell survival is the prevention of apoptosis. Through the 
304 breakdown of forkhead box O3 (FOXO3), Akt prevents the activation of p27, p21 
305 p15, and p19, along with other proapoptotic genes such as BH3-only protein, Fas 
306 ligand and the p53 upregulated modulator of apoptosis [88]. Studies of primary 
307 chronic lymphatic leukemia B cells show that the constitutively active Akt increases 
308 expression and stability of the induced myeloid leukemia cell differentiation protein 
309 Mcl-1, the X-linked inhibitor of apoptosis protein and antiapoptotic B-cell lymphoma-
310 extra large proteins, thus contributing to the inhibition of apoptosis & extending the 
311 longevity of diseased cells [78]. Furthermore, the cytochrome C induced apoptotic 
312 signaling pathway is inhibited by Akt at caspase 9, thereby promoting cell survival 









321 Another key hallmark of cancer is the switch towards anaerobic metabolism, 
322 described as the Warburg Effect [89].  This avoids the reliance on oxygen for energy 
323 production and is often correlated with tumor aggressiveness as it equips the cells 
324 with a rapid source of energy and intermediates for growth [90-93]. Targeting 
325 enzymes that promote the Warburg effect, such as the PI3K/Akt/mTOR pathway, act 
326 as a promising strategy to target the metabolic adaptations of cancer cells [94-97]. 
327
328 By phosphorylating the AS160 substrate on the glucose transporter type 4 receptor, 
329 AKT prompts its translocation to the cell surface and increases the cell’s intake of 
330 glucose [98]. Downstream from the mTOR axis, there is the activation of other 
331 metabolism modulations that act to promote energy production and consumption 
332 within the cell [99]. PI3K phosphorylation and inhibition of FOXO1 and (downstream) 
333 CREB regulated transcription coactivator 2 inhibiting the fasting regulation of 
334 gluconeogenesis [100]. Storage of this excess glycogen is promoted through the 
335 inhibition of the glycogen synthase GSK3, which indirectly lowers the levels of c-
336 Myc (noted in leukemic blast cells) [101]. Overall this prevents the inhibition of the 
337 hypoxic induced gene, promoting the Warburg Effect [102].
338
339 6.0 Targeting PI3K/Akt/mTOR
340
341 A genetic study of 218 prostate cancer tumors showed that 42% of primary growths 
342 and 100% of metastasizes displayed a genomic dysregulation of the PI3K/Akt/mTOR 
343 pathway [13], thus targeting key axis points within this pathway might be vital in 
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344 reducing the aggressiveness CRPCa. A meta-analysis in 2018 suggested that 
345 PI3K/Akt/mTOR pathway inhibitors can significantly improve the survival of patients 
346 with advanced solid tumors [74]. With a range of synthetic inhibitors being proposed, 
347 including dual mTORC1/2, dual PI3K/mTOR, Pan-PI3K, isoform-specific PI3K, and 
348 second-generation Akt inhibitors (Table 4), the therapeutic demand for a range of 
349 PI3K/Akt/mTOR inhibitors is evident.  
350
351 6.1 Evidence for EGCGs role
352
353 EGCG itself acts as a competitive inhibitor (Ki 380 nM) of the common class 1 
354 isomers of PI3K (PI3K, PI3K, PI3K, and PI3K), preventing the initial 
355 phosphorylation of Akt [103-108].  The binding mode of EGCG is noted to be similar 
356 to the PI3K inhibitor LY294002 [37]. It should be noted that within the LNCaP and 
357 PC-3 PCa cell lines, EGCG had no significant effect on the phosphorylation of PI3K 
358 at the Ser437 residue. The lack of the phosphatase and tensin homolog allele was 
359 suspected to cause the non-response [37]. EGCG also inhibits mTOR (Ki of 320 ± 
360 24 nM [37], aligning itself in a similar category to the synthetic dual PI3K/Akt/mTOR 
361 inhibitors. These non-selective inhibitors display more promising effects as both pre-
362 clinically and clinically, they are better equipped at overcoming the compensatory 
363 feedback mechanisms [37, 103-105].
364
365 Including its activity against the central PI3K/Akt/mTOR axis points, EGCG also 
366 interferes with the signaling cascade downstream from mTOR to reactivate the 
367 apoptotic signaling. Similar to other chemopreventive natural products such as 
368 curcumin, caffeinic acid, and capsaicin, EGCG is inhibitory against the transcription 
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369 factor; nuclear factor kappa-light-chain-enhancer of activated B cells (NF- KB) [109]. 
370 NF- KB is redox-responsive, and is highly implicated with the cancer cell proliferation 
371 and survival [110-112]. Although not specifically in PCa, when the squamous cell 
372 carcinomas cell line, A431 was treated with doses of 30-80 M of EGCG, the EGCG 
373 was seen to suppress the activation of NF- KB, to which there is substantial evidence 
374 of crosstalk between the two pathways  [113] [114]. Depleting the levels of NF- KB in 
375 both the nucleus and cytoplasm, cancer cells were no longer protected against 
376 apoptosis, resulting in cell death [115]. Comparing the responsive dose of EGCG 
377 required to inhibit NF- KB displayed an evident selectivity towards the cancerous 
378 A431 cell line over the non-cancerous normal human epidermal keratinocytes [109]. 
379 Furthermore, with the correlation between NF- KB expression and PCa resistance 
380 against Docetaxel, the inhibition of NF- KB (via BAY11-7082 inhibitor), appeared to 
381 reverse this resistance, and maybe the key to improving the efficacy of PCa drugs 
382 [116].
383
384 As a catechin, EGCG has a single-electron reduction potential enabling it to act as a 
385 scavenger for reactive oxygen species (ROS), and its pro-oxidant nature strongly 
386 contributes to pro-apoptotic activity. EGCG is susceptible to oxidation by H2O2 [36, 
387 117, 118]. The then oxidized EGCG forms a cytotoxic o-quinone, which later reacts 
388 with glutathione to form various ROS [118, 119]. These ROS are suspected to 
389 downregulate Bcl-2 and Mcl-1 [36, 120]. When EGCG is administered in combination 
390 with arsenic trioxide (Trisenox®), a natural product based chemotherapeutic used in 
391 acute promyelocytic leukemia, the production of ROS was greater than seen with 
392 either used alone [36]. EGCG also displays some selectivity to cancerous cells, with 
393 apoptosis induced in the cancerous A431 cell line, but not normal epidermal 
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394 keratinocyte counterparts [109]. Thus, the combined increase in ROS and depletion 
395 of NF-kB, EGCG is seen to counteract the prosurvival signaling enacted by 
396 PI3K/Akt/mTOR hyperactivation. 
397
398 7.0 Discussion and Conclusion
399
400 There a deficit in our collective knowledge in the area of EGCG’s role in the 
401 occurrence and treatment of cancer, as well as that of tea products in this same 
402 area, and this is indicative of the future work that might be done to address this. Due 
403 to EGCG being considered a pan assay interference compound, it can be assumed 
404 that other pathways are affected beyond PI3K/Akt/mTOR since its structural 
405 properties are conducive to broad interactions [121, 122]. Thus, there is a concern 
406 with its use to guide synthetic drug design. EGCG also has poor stability, it rapidly 
407 oxidizes in solution, and is rapidly metabolized in vivo [123-125]. Even so, the 
408 evidence provided in laboratory and clinical studies gives encouraging support for 
409 the further investigation of this phytochemical and its botanical source. Further study 
410 may take the form of clinical trials to assess the use of EGCG or tea products as 
411 adjunct natural therapies alongside traditional chemotherapy, or another promising 
412 area of work may be computational analysis for guided drug design, with EGCG as a 
413 lead compound.  Although there is the potential for nonspecific interactions of such 
414 compounds when examined via in vitro assay, in vivo evidence encourages research 
415 to continue in this area.                
416
417 Overcoming the metabolic adaptations of metastatic prostate cancer continues to be 
418 a major hurdle in producing effective treatments without severely hindering the 
19
419 patient's quality of life. Due to the multifactorial nature of many cancers, in particular, 
420 CRPCa, single-target drugs are often redundant due to crosstalk within the 
421 prosurvival cascades, such as the PI3K/Akt/mTOR pathway. However, natural 
422 product EGCG may hold the solution. Acknowledged for its tolerability and 
423 chemotherapeutic activity against a variety of cancers, EGCG acts upon a range of 
424 targets within the PI3K/Akt/mTOR cascade to promote the selective apoptosis of 
425 cancer cells. With a growing risk of many late-stage cancers, investigating tolerable 
426 options such as EGCG may be essential for cancer treatment going forward. 
427 Whether effective on its own or to be utilized as adjuvant therapy, EGCG shows 
428 potential as a chemopreventative or sensitizer and may have the potential to lead 
429 further synthetic drug design. 
430
431
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838 Figure 1: Generalized processing protocol for Green, Oolong and Black Tea. Primary 
839 differences in the catechin content of each tea variety result from the variation in 







846 Figure 2: Key bioactive components of green tea, broadly categorized into flavonoids, 
847 methylxanthines, vitamins and other.
848



































850 Figure 3: Names and structures of the 2-phenylbenzopyrans (flavonoids), in which 








857 Figure 5: Structures of semi-synthetic and natural products used in chemotherapy
42
858
859 Figure 6: Activation of PI3K and Akt mediated through (a) mitogenic activation at the 
860 receptor tyrosine kinase (RTK) resulting in the (2) phosphorylation and binding of the 
861 PI3K intracellular unit (3) conversion of PIP2 to PIP3 and activation of the Ph subunit 
862 on Akt inducing the translocation to the cell membrane (4) phosphorylation and 
863 activation of Akt. Abbreviations: receptor tyrosine kinase (RTK), Phosphatidylinositol-
864 4,5-bisphosphate 3-kinase (p85/p110kin), Phosphatidylinositol 4,5-bisphosphate (PIP), 




867  11.0 Tables 
868
Table 1: Proportion of Catechins present in Tea
Fermentation % Flavanols
Non-Fermented (Green) 8.0–14.4 
Partially Fermented (Oolong) 4.14–4.92 
Fermented (Black) 0.24–0.51
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Table 2: EGCG’s association as a chemopreventive with a range of cancers.
Cancer Effect of EGCG  Source
Cellular apoptosis [109]Prostate




Keratinocytes Cellular apoptosis [109]
Reduced Risk [36]Bladder 
Carcinoma
 
Chemoprevention [4, 5] 
Prevent reoccurrence [33]







Inhibit tumour development (mouse/rat) [57] 
Controversial association with efficacy [4]






Elevate ROS production during apoptosis [36]
Lymphatic
Cellular apoptosis (mouse LY5178) [109]
Reduced adenocarcinoma incidence (Polyphenol E*) [57]
Reduced adenocarcinoma multiplicity (Polyphenol E*) [57]
Increase phosphorylation of cJun [130, 131] 
Increase phosphorylation of Erk1/2 [131]
Increase PCNA [131]
G0/G1 halt in A431 (not non-cancerous NHEK) [11]
Constitutively expression of NF-kB [109]
Epidermal
Apoptotic cell death [109]
(Inflammation) Protect against collagen-induced arthritis (GTP**) [109] 
Esophageal Chemopreventive [4, 57] 
Stomach Chemopreventive [4, 57]
Intestine Chemopreventive [4, 57]




Table 3: Eligibility criteria and common side effects for current PCa treatments.
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Locally advanced inoperable 
prostate cancer in combination 
with radiation therapy Locally 
advanced or metastatic castrate-
resistant prostate cancer in 
combination with LHRH agonist 
Short term prevention of tumor 
flare associated with the initiation 
of an LHRH agonist







secondary hormonal therapeutic. 
Must be in combination with 
prednisone or prednisolone, and 
no other chemotherapy






Post-docetaxel CRPCa. Available 
for clinical trials secondary 















Locally advanced or metastatic 
castrate resistant prostate cancer. 
Used in combination with LHRH 
agonist throughout treatment. 
















Asymptomatic or minimally 
metastatic CRPCa
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PI3K Inhibitors AZD 8186 
GSK2141795 Uprosertib
GDC-0068 IpatasertibAKT Akt 
AZD5363  
















































































































































Lung cancer, ovarian cancer
GlaxoSmithKline, October 2007
Camptothecin (CPT)















Docetaxel (DTX, DXL, Taxotere)
Breast, ovarian, lung, bladder, prostate, melanoma, esophageal
Sanofi-Aventis June 1998 















Paclitaxel (PTX or Taxol)

















Rosy Periwinle Catharanthus roseus
Acute lymphocytic leukemia, acute myeloid 
leukemia, Hodgkin's disease, neuroblastoma, and 
small cell lung cancer
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Fermented (Black) 0.24–0.51
Table 2: EGCG’s association as a chemopreventive with a range of cancers.
Cancer Effect of EGCG  Source
Cellular apoptosis [109]Prostate




Keratinocytes Cellular apoptosis [109]
Reduced Risk [36]Bladder 
Carcinoma
 
Chemoprevention [4, 5] 
Prevent reoccurrence [33]







Inhibit tumour development (mouse/rat) [57] 
Controversial association with efficacy [4]






Elevate ROS production during apoptosis [36]
Lymphatic
Cellular apoptosis (mouse LY5178) [109]
Reduced adenocarcinoma incidence (Polyphenol E*) [57]
Reduced adenocarcinoma multiplicity (Polyphenol E*) [57]
Increase phosphorylation of cJun [130, 131] 
Increase phosphorylation of Erk1/2 [131]
Increase PCNA [131]
G0/G1 halt in A431 (not non-cancerous NHEK) [11]
Constitutively expression of NF-kB [109]
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Apoptotic cell death [109]
(Inflammation) Protect against collagen-induced arthritis (GTP**) [109] 
Esophageal Chemopreventive [4, 57] 
Stomach Chemopreventive [4, 57]
Intestine Chemopreventive [4, 57]
*polyphenol E is a concentrated catechin preparation; ** GTP refers to a combination of green tea 
proteins;
Table 3: Eligibility criteria and common side effects for current PCa treatments.


































































locally advanced or metastatic 



























Locally advanced inoperable 
prostate cancer in combination 
with radiation therapy Locally 
advanced or metastatic castrate-
resistant prostate cancer in 
combination with LHRH agonist 
Short term prevention of tumor 
flare associated with the initiation 
of an LHRH agonist







secondary hormonal therapeutic. 
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in combination with prednisone or 
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Diarrhea
Note that this table is not fully comprehensive and the most current Australian data can be found at the EviQ 
[132-140]
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